S3-E54.2 – Presentation on Efruxifermin in NASH with Fibrosis

S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis
On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.

Last month, Stephen Harrison joined the Surf to cover a recent string of press releases presaging some of the most promising data of the last decade in NASH drug development. As Principal Investigator, he reviewed Phase 2b results from Akero’s HARMONY Trial. This is a 24-week study evaluating the efficacy and safety of the FGF-21 agonist efruxifermin (EFX) in patients with clinically relevant NASH (F2-F3).

The topline results he previously shared:

The study met its primary endpoint for both the 50mg and 28mg EFX dose groups.

Respectively, 41% and 39% of EFX-treated patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 24 (compared with 20% for the placebo arm).

In this follow-up conversation, Stephen walks through his presentation on Akero’s lead product candidate EFX. After detailing the data, two important points emerge. First, Stephen and Sven Francque share the idea that “not all FGF-21’s are created equal.” FGF-21’s themselves need to be stabilized due to their two-hour half-lives. The first FGF-21, pegbelfermin, was PEGylated and revealed significant challenges in clinical development. EFX is a bivalent structure – two molecules stabilized by a fusion protein. This appears to work far better. The conversation continues with more points and questions about the study results and implications. An interesting idea surfaces: EFX might function better as an induction therapy to be followed by an oral maintenance therapy as a long-term monotherapeutic solution. As the session winds down, the group speculate the dynamics of what happens when disease regresses to a point where there is far less liver damage.